B-HT 958 and SND 919, two selective agonists at D2 dopamine receptors, were examined for their influence on the feeding behavior of fasted rats. When food intake was determined in the rat's individual home cage, it was found to be reduced by both drugs at low sedative doses during the first hour after treatment and by SND 919 at the highest dose (which also elicits stereotypy) only 24 h later. However, SND 919 and B-HT 958 had no significant effect on feeding evaluated according to the X-maze and tube feeding tests. Analysis of the results, seen in the context of other behavioral signs produced by the drugs, suggests that data on feeding may vary depending on the experimental model used and can be modified by extraneous factors that interfere with a specific effect on food intake.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0031-9384(94)90324-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Differential Effects of Dopamine Agonists and Clonazepam on Large Muscle Group Movements in Restless Legs Syndrome.
Sleep
January 2025
Clinical Neurophysiology Research Unit and Sleep Research Centre, Oasi Research Institute-IRCCS, Troina, Italy.
Study Objectives: This study aimed to investigate the effect of dopamine agonists (DA) and Clonazepam on Large Muscle Group Movements during sleep (LMM), a distinct motor phenomenon, in Restless Legs Syndrome (RLS).
Methods: A retrospective analysis was conducted on 51 drug-free adult patients with RLS, divided into three groups: 33 received a DA (pramipexole or ropinirole), 15 received clonazepam, and 18 received a placebo. Each patient underwent two consecutive nocturnal polysomnographic (PSG) recordings: one baseline and one following treatment administration.
Creativity and Mental Illness: A Case Study of a Patient with Progressive Bulbar Palsy.
Brain Sci
November 2024
Clinical Neuroanatomy, Department of Neurology, University Hospital Ulm, 89081 Ulm, Germany.
Creativity and the production of artwork can have an impact on the course and treatment of comorbid severe mental illness and neurodegeneration. We report on a 70-year-old male patient with highly original artistic behavior, who suffered from lifelong recurrent major depression and subsequently developed symptoms of progressive bulbar palsy (PBP). In the context of a systematic literature review, we detail the patient's personal and artistic biographies and portray artwork from his artistic portfolio together with his disease history, clinical examination, psychopathological and neuropsychological evaluations, blood and cerebrospinal fluid analyses, neuroimaging, neurophysiological testing, and psychotherapeutic treatment.
View Article and Find Full Text PDFPramipexole decreases allodynia and hyperalgesia via NF-κB in astrocytes in rats with Parkinson's disease.
Pharmacol Biochem Behav
December 2024
Departamento de Neurobiología del Desarrollo y Neurofisiología, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Boulevard Juriquilla, No. 3001, C.P. 76230, Querétaro, Mexico.
Pain is one of the principal non-motor symptoms of Parkinson's disease (PD), negatively impacting the patient's quality of life. This study aimed to demonstrate whether an effective dose of pramipexole (PPX) can modulate the NF-κB/p-p65 activation in glial cells (astrocytes and microglia) and diminish the hypersensitivity (allodynia and hyperalgesia) in male Wistar rats with PD. For this, 2 μl of 6-hydroxydopamine (6-OHDA, 8 μg/μL/0.
View Article and Find Full Text PDFThe Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease.
Actas Esp Psiquiatr
December 2024
Department of Neurology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, 210003 Nanjing, Jiangsu, China.
Background: Parkinson's disease (PD), a prevalent neurological condition, is characterized by the progressive degeneration of dopamine-producing neurons, leading to motor dysfunction and non-motor symptoms. Therefore, this study aimed to evaluate the impact of combining levodopa/benserazide with pramipexole on PD patients, focusing on cognitive function, plasma monoamine neurotransmitter levels, and serum growth differentiation factor-15 (GDF-15) and angiopoietin-1 (Ang-1) levels.
Methods: This retrospective study included 120 PD patients admitted to the hospital between January 2021 and January 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!